Cedax: profile and news

Biovail Reports Third-Quarter 2005 Financial Results Nov 11, 2005
...year-over-year declines in total prescription volumes for these mature products, and the termination of the sub-licensing agreement for Cedax in August 2004. ... - Business Wire (press release),

Biovail Reports Second-Quarter 2005 Financial Results Aug 4, 2005
...year-over-year declines in total prescription volumes for these mature products, and the termination of the sub-licensing agreement for Cedax in August 2004. ... - Business Wire (press release)

Biovail Reports First-Quarter 2005 Financial Results May 5, 2005
...year-over-year declines in total prescription volumes for these mature products, and the termination of the sub-licensing agreement for Cedax in August 2004. ... - Business Wire,

Biovail Reports Fourth Quarter, Year-End 2004 Financial Results Mar 10, 2005
...reduction in wholesaler inventory levels, the genericization of Tiazac in April 2003 and the termination in August 2004 of the sub-licensing agreement for Cedax ... - Business Wire (press release),

Other information

Indication
For the treatment of the following infections (respiratory, skin, soft tissue, urinary tract infections, ear, nose, throat infectsion) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A ß-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph. Also used to treat acute bacterial bronchitis in patients with COPD

Pharmacology
Cefuroxime, a second-generation cephalosporin, is used to treat severe upper and lower respiratory tract infections, skin infections, otitis media, and surgical prophylaxis.

Mechanism Of Action
Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.

Drug Category
Anti-bacterial Agents; Cephalosporins; ATC:J01DC02

Brand Names/Synonyms
Ancef; Biofuroksym; Ceclor; Ceclor Cd; Cedax; Cefditoren; Cefizox; Cefotan; Ceftin; Ceftizoxime Sodium; Cefurax; Cefuril; Cefuroxim; Cefuroxime; Cefuroxime Axetil; Cefuroxime Free Acid; Cefuroxime Sodium; Cefuroxime Sodium Salt; Cefuroxime [Usan:Ban:Inn]; Cefuroxime and Dextrose in Duplex Container; Cefuroximo [Inn-Spanish]; Cefuroximum [Inn-Latin]; Cefzil; Cephuroxime; Ceptaz; Duricef; Elobact; Fortaz; Keflex; Keftab; Kefurox; Kefurox in Plastic Container; Kerurox; Mandol; Maxipime; Mefoxin; Monocid; Omnicef; Oraxim; Rocephin; Sharox; Tazicef; Vantin; Velosef; Zinacef; Zinacef Danmark; Zinacef in Plastic Container; Zinat; Zinnat

Dosage Forms
POWDER; POWDER FOR SOLUTION; TABLET

Absorption
Well absorbed from the GI tract (bioavailability is 37-52%)

Interactions
-->Interactions for Cefuroxime:

Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedictís or Fehlingís solution or with ClinitestÒ tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.

Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.

Chemical IUPAC Name
4-(carbamoyloxymethyl)-8-[2-(2-furyl)-2-methoxyimino-acetyl]amino-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid

Chemical Formula
C16H16N4O8S

Half Life
~80 minutes

Drug Type
Approved Drug

# Accession No
APRD00285

CAS Registry Number
55268-75-2